Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 1:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 144 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Primary Amyloidosis of Light Chain Type Clear all
Completed Phase 2 Interventional Results available

The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis

NCT02632786
View directory record Official record
Conditions
AL Amyloidosis
Interventions
NEOD001, Placebo
Drug
Lead sponsor
Prothena Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
19
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Sep 25, 2026, 1:27 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

NCT07224672
View directory record Official record
Conditions
Amyloidosis
Interventions
Belantamab mafodotin, Cyclophosphamide, Bortezomib, Dexamethasone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

NCT03499808
View directory record Official record
Conditions
Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea, Early Satiety, Gastrointestinal Hemorrhage, Hepatomegaly, Lymphadenopathy, Macroglossia, Nausea, Primary Systemic Amyloidosis, Purpura, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
Interventions
Isatuximab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
345
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Burbank, California + 234 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 1 Interventional

A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis

NCT05201911
View directory record Official record
Conditions
Amyloidosis; Systemic
Interventions
124I-AT03
Drug
Lead sponsor
Attralus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Sep 25, 2026, 1:27 AM EDT
Terminated Not applicable Interventional Results available

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

NCT00726830
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Spartanburg, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Sep 25, 2026, 1:27 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of AT-02 in Subjects With Systemic Amyloidosis.

NCT05951049
View directory record Official record
Conditions
Amyloidosis; Systemic
Interventions
AT02
Drug
Lead sponsor
Attralus, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Kansas City, Kansas • Cleveland, Ohio • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 25, 2026, 1:27 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

NCT05451771
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg, Dexamethasone Oral, 10 mg, Dexamethasone Oral, 20 mg, Daratumumab Injection, Bendamustine, Pomalidomide, Ixazomib, Venetoclax MTD with Dexamethasone
Drug · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Boston, Massachusetts • Rochester, Minnesota • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

NCT01083316
View directory record Official record
Conditions
Amyloidosis
Interventions
Bortezomib, Dexamethasone, Melphalan
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Daratumumab for the Treatment of Patients With AL Amyloidosis

NCT02841033
View directory record Official record
Conditions
AL Amyloidosis
Interventions
daratumumab
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies

NCT05028374
View directory record Official record
Conditions
Multiple Myeloma, AL Amyloidosis, Chronic Lymphocytic Leukemia
Interventions
A single "booster" dose of the Moderna mRNA COVID-19 vaccine
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 25, 2026, 1:27 AM EDT
Terminated Phase 1 Interventional

A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis

NCT04115956
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Melphalan-Flufenamide (Melflufen), Dexamethasone
Drug
Lead sponsor
Oncopeptides AB
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 1 Interventional

PS-341 in Treating Patients With Advanced Cancer

NCT00006362
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
2
States / cities
Rochester, Minnesota • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 2, 2011 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 1Phase 2 Interventional

124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis

NCT03678259
View directory record Official record
Conditions
Systemic Amyloidosis
Interventions
124I-p5+14 Injection
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 25, 2026, 1:27 AM EDT
Recruiting Phase 1 Interventional

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

NCT05652335
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
Interventions
JNJ-79635322
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
9
States / cities
Duarte, California • Irvine, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 3 Interventional

St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer

NCT00005805
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
St. John's wort
Dietary Supplement
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 25, 2026, 1:27 AM EDT
Recruiting Not applicable Interventional

Molecular Imaging of Primary Amyloid Cardiomyopathy

NCT02641145
View directory record Official record
Conditions
Amyloidosis, Primary, Cardiomyopathy
Interventions
F-18 florbetapir/C-11 acetate PET, MRI, N-13 ammonia PET
Radiation · Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 2 Interventional

Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis

NCT00007995
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, recombinant interferon alfa, sargramostim, busulfan, cyclophosphamide, melphalan, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Advanced Cancer

NCT00003331
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fluorouracil, leucovorin calcium, topotecan hydrochloride
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2011 · Synced Sep 25, 2026, 1:27 AM EDT
Terminated Phase 1 Interventional

Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis

NCT00030381
View directory record Official record
Conditions
Primary Systemic Amyloidosis
Interventions
4'-iodo-4'-deoxydoxorubicin, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 25, 2026, 1:27 AM EDT
Recruiting Phase 2 Interventional

Teclistamab-Daratumumab in AL Amyloidosis

NCT07110844
View directory record Official record
Conditions
Amyloid Light-chain Amyloidosis
Interventions
Teclistamab, Daratumumab and Hyaluronidase-fihj
Drug
Lead sponsor
Rajshekhar Chakraborty, MD
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 25, 2026, 1:27 AM EDT
Completed Phase 1Phase 2 Interventional

Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

NCT01707264
View directory record Official record
Conditions
Primary Amyloidosis
Interventions
NEOD001
Drug
Lead sponsor
Prothena Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Palo Alto, California • Boston, Massachusetts • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Sep 25, 2026, 1:27 AM EDT
Recruiting No phase listed Observational

Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource

NCT01408225
View directory record Official record
Conditions
Plasma Cell Dyscrasias, Monoclonal Gammopathy of Undetermined Significance, AL Amyloidosis, Multiple Myeloma
Interventions
tissue banking
Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2050
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 25, 2026, 1:27 AM EDT
Terminated Phase 2 Interventional Results available

2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis

NCT00075608
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
filgrastim, melphalan, autologous stem cell transplantation, stem cell infusion
Biological · Drug · Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Sep 25, 2026, 1:27 AM EDT
Completed No phase listed Observational

Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone

NCT00993694
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Methemoglobinemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions
chemotherapy, dapsone, medical chart review, assessment of therapy complications
Drug · Other · Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
Up to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 25, 2026, 1:27 AM EDT